SemaThera Inc

📍 Westmount, Canada🗓 Founded 2016👥 6 employees💰 Last funded Mar 2018
Biotechnology Research🌐 semathera.com
Website LinkedIn
SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2016
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Canada
3
Investor activity2017–2018 · investors recorded per year
2017220181
Recent (last 2y)Earlier
Frequently asked questions
Who invested in SemaThera Inc?
SemaThera Inc has 3 investors on record on gritt.io, including 3 early-stage backers.
When did SemaThera Inc last raise funding?
The most recent investment in SemaThera Inc recorded on gritt.io was in March 2018.
When was SemaThera Inc founded?
SemaThera Inc was founded in 2016.
What industry is SemaThera Inc in?
SemaThera Inc operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is SemaThera Inc based?
SemaThera Inc is headquartered in Westmount, Canada.